126 related articles for article (PubMed ID: 38835325)
1. Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure.
Bae JH; Park JB; Baek JE; Hong SW; Park SH; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Hwang SW
Gut Liver; 2024 Jun; ():. PubMed ID: 38835325
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience.
Jeffrey AW; Abu-Rgeef R; Picardo S; Menon S; So K; Venugopal K
Ann Gastroenterol; 2023; 36(5):549-554. PubMed ID: 37664232
[TBL] [Abstract][Full Text] [Related]
4. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.
Hong SN; Hye Song J; Jin Kim S; Ha Park Y; Wan Choi C; Eun Kim J; Ran Kim E; Kyung Chang D; Kim YH
Inflamm Bowel Dis; 2024 Apr; 30(4):517-528. PubMed ID: 37260346
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
6. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
Alten R; An Y; Kim DH; Yoon S; Peyrin-Biroulet L
Clin Drug Investig; 2022 Jun; 42(6):477-489. PubMed ID: 35657560
[TBL] [Abstract][Full Text] [Related]
7. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Schreiber S; Ben-Horin S; Leszczyszyn J; Dudkowiak R; Lahat A; Gawdis-Wojnarska B; Pukitis A; Horynski M; Farkas K; Kierkus J; Kowalski M; Lee SJ; Kim SH; Suh JH; Kim MR; Lee SG; Ye BD; Reinisch W
Gastroenterology; 2021 Jun; 160(7):2340-2353. PubMed ID: 33676969
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
Buisson A; Nachury M; Reymond M; Yzet C; Wils P; Payen L; Laugie M; Manlay L; Mathieu N; Pereira B; Fumery M
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2338-2346.e3. PubMed ID: 35987302
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
Buisson A; Nachury M; Bazoge M; Yzet C; Wils P; Dodel M; Coban D; Pereira B; Fumery M
Aliment Pharmacol Ther; 2024 Feb; 59(4):526-534. PubMed ID: 38037279
[TBL] [Abstract][Full Text] [Related]
10. Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Hupé M; Streichenberger A; Wils P; Arab N; Serrero M; Amiot A; Bozon A; Vuitton L; Fumery M; Altwegg R; Nachury M; Hébuterne X; Yzet C; Coban D; Dodel M; Bazoge M; Pereira B; Buisson A
Dig Liver Dis; 2024 Jan; ():. PubMed ID: 38281870
[TBL] [Abstract][Full Text] [Related]
11. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Calafat M; Torres P; Tosca-Cuquerella J; Sánchez-Aldehuelo R; Rivero M; Iborra M; González-Vivo M; Vera I; de Castro L; Bujanda L; Barreiro-de Acosta M; González-Muñoza C; Calvet X; Benítez JM; Llorente-Barrio M; Surís G; Cañete F; Arias-García L; Monfort D; Castaño-García A; Garcia-Alonso FJ; Huguet JM; Marín-Jímenez I; Lorente R; Martín-Cardona A; Ferrer JÁ; Camo P; Gisbert JP; Pajares R; Gomollón F; Castro-Poceiro J; Morales-Alvarado J; Llaó J; Rodríguez A; Rodríguez C; Pérez-Galindo P; Navarro M; Jiménez-García N; Carrillo-Palau M; Blázquez-Gómez I; Sesé E; Almela P; Ramírez de la Piscina P; Taxonera C; Rodríguez-Lago I; Cabrinety L; Vela M; Mínguez M; Mesonero F; García MJ; Aguas M; Márquez L; Silva Porto M; Pineda JR; García-Etxebarría K; Bertoletti F; Brunet E; Mañosa M; Domènech E
Therap Adv Gastroenterol; 2024; 17():17562848231221713. PubMed ID: 38187926
[TBL] [Abstract][Full Text] [Related]
12. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
[TBL] [Abstract][Full Text] [Related]
13. Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial.
Schreiber S; D'Haens G; Cummings F; Irving PM; Ye BD; Ben-Horin S; Kim DH; Jeong AL; Reinisch W
Dig Liver Dis; 2024 Feb; ():. PubMed ID: 38365502
[TBL] [Abstract][Full Text] [Related]
14. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A; Straatmijer T; Duijvestein M; Sales A; Levran A; van Schaik F; Maljaars J; Gecse K; Ponsioen C; Grootjans J; Hanzel J; Tack G; Jansen J; Hoentjen F; de Boer N; van der Marel S; Dijkstra G; Oldenburg B; Löwenberg M; van der Meulen A; D Haens G;
Aliment Pharmacol Ther; 2022 Sep; 56(6):1044-1054. PubMed ID: 35869807
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission.
Viazis N; Pontas C; Manolakis A; Karampekos G; Tsoukali E; Galanopoulos M; Koustenis K; Archavlis E; Christidou A; Gazouli M; Mantzaris GJ
Acta Gastroenterol Belg; 2021; 84(3):423-428. PubMed ID: 34599566
[TBL] [Abstract][Full Text] [Related]
17. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
[TBL] [Abstract][Full Text] [Related]
18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
19. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
Sandborn WJ; Chen J; Kisfalvi K; Loftus EV; D'Haens G; Candela N; Lasch K; Wolf DC; Uddin SM; Danese S
Crohns Colitis 360; 2023 Jul; 5(3):otad034. PubMed ID: 37636008
[TBL] [Abstract][Full Text] [Related]
20. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
